Buy Cadila Healthcare; target of Rs 550: Motilal Oswal

Motilal Oswal is bullish on Cadila Healthcare has recommended buy rating on the stock with a target price of Rs 550 in its research report dated February 06, 2021.

Buy Cadila Healthcare; target of Rs 555: ICICI Direct

ICICI Direct is bullish on Cadila Healthcare has recommended buy rating on the stock with a target price of Rs 555 in its research report dated February 06, 2021.

Cadila: COVID vaccine to be the key differentiator in the near term

In the next fiscal, Cadila plans to launch 40-plus products, including 8-10 complex molecules which should offset pricing erosion

Buy Cadila Healthcare; target of Rs 655: Emkay Global Financial

Emkay Global Financial is bullish on Cadila Healthcare has recommended buy rating on the stock with a target price of Rs 655 in its research report dated January 22, 2021.

COVID Vaccine: The opportunities for investors - Part I

Vaccine rollout will throw up opportunities not just for the domestic pharmaceutical and healthcare industry but also the logistics value chain, right from vaccine production, delivery, storage and then the actual immunisation

Accumulate Cadila Healthcare; target of Rs 497: Dolat Capital Market

Dolat Capital Market recommended accumulate rating on Cadila Healthcare with a target price of Rs 497 in its research report dated November 02, 2020.

Buy Cadila Healthcare; target of Rs 555: ICICI Direct

ICICI Direct is bullish on Cadila Healthcare has recommended buy rating on the stock with a target price of Rs 555 in its research report dated November 03, 2020.

Sell Cadila Healthcare; target of Rs 357: Prabhudas Lilladher

Prabhudas Lilladher is bearish on Cadila Healthcare has recommended sell rating on the stock with a target price of Rs 357 in its research report dated November 03, 2020.

Buy Cadila Healthcare: target of Rs 530: Sharekhan

Sharekhan is bullish on Cadila Healthcare recommended buy rating on the stock with a target price of Rs 530 in its research report dated November 03, 2020.

Cadila: a formidable play in Covid times and beyond

Cadila is not only a credible Indian pharma striving for a Covid solution, but on a longer time scale is an interesting watch in the large-cap space witnessing a significant transformation in product portfolio.

Reduce Cadila Healthcare; target of Rs 408: Dolat Capital

Dolat Capital recommended reduce rating on Cadila Healthcare with a target price of Rs 408 in its research report dated August 14, 2020.

Buy Cadila Healthcare; target of Rs 470: ICICI Direct

ICICI Direct is bullish on Cadila Healthcare has recommended buy rating on the stock with a target price of Rs 470 in its research report dated August 06, 2020.

Reduce Cadila Healthcare; target of Rs 408: Dolat Capital

Dolat Capital recommended accumulate rating on Cadila Healthcare with a target price of Rs 408 in its research report dated August 05, 2020.

Hold Cadila Healthcare; target of Rs 402: Emkay Global Financial

Emkay Global Financial recommended hold rating on Cadila Healthcare with a target price of Rs 402 in its research report dated August 05, 2020.

Sell Cadila Healthcare; target of Rs 329: Prabhudas Lilladher

Prabhudas Lilladher is bearish on Cadila Healthcare has recommended sell rating on the stock with a target price of Rs 329 in its research report dated August 06, 2020.

Hold Cadila Healthcare; target of Rs 445: Sharekhan

Sharekhan recommended Hold rating on Cadila Healthcare with a target price of Rs 445 in its research report dated August 05, 2020.

Buy Cadila Healthcare; target of Rs 460: Motilal Oswal

Motilal Oswal is bullish on Cadila Healthcare recommended buy rating on the stock with a target price of Rs 460 in its research report dated August 06, 2020.

Buy Cadila Healthcare; target of Rs 420: ICICI Direct

ICICI Direct is bullish on Cadila Healthcare has recommended buy rating on the stock with a target price of Rs 420 in its research report dated June 22, 2020.

Buy Cadila Healthcare; target of Rs 420: Motilal Oswal

Motilal Oswal is bullish on Cadila Healthcare has recommended buy rating on the stock with a target price of Rs 420 in its research report dated June 20, 2020.

Hold Cadila Healthcare: target of Rs 380: Sharekhan

Sharekhan recommended Hold rating on Cadila Healthcare with a target price of Rs 380 in its research report dated June 19, 2020.

Pharma companies that can benefit from the demand for complex respiratory drugs

Hold Cadila Healthcare; target of Rs 285: ICICI Direct

ICICI Direct recommended hold rating on Cadila Healthcare with a target price of Rs 285 in its research report dated February 10, 2020.

Hold Cadila Healthcare; target of Rs 247: Prabhudas Lilladher

Prabhudas Lilladher recommended hold rating on Cadila Healthcare with a target price of Rs 247 in its research report dated February 06, 2020.

Hold Cadila Healthcare; target of Rs 220: Prabhudas Lilladher

Prabhudas Lilladher recommended Hold rating on Cadila Healthcare with a target price of Rs 220 in its research report dated November 13, 2019.

Hold Cadila Healthcare target of Rs 275: Sharekhan

Sharekhan recommended Hold rating on Cadila Healthcare with a target price of Rs 275 in its research report dated November 14, 2019.